Objective: To estimate the cost-effectiveness of the use of drug-eluting stent compared to bare-metal stent in a cohort of patients with coronary disease in the Social Security Mexican Institute (IMSS). Methods: Cost-effectiveness in a cohort of patients with ischemic disease with indication of PCI (Percutaneous Coronary Intervention). The measure of effectiveness was the rate of clinical success without major cardiovascular adverse events. The cost and effectiveness of the treatment were obtained from clinical follow-up of the cohort from 104 patients in the Cardiology Hospital of IMSS. The micro-costing technique was used, and the costs come from bases institutional costs. The results are expressed in US dollars (US$) in 2007. Given the time horizon of the study (12 months), the discount rate was not applie. We performed a sensitivity analysis probabilistic, and I think the curve of acceptability. Results: The 61.5% of patients in the cohort used bare-metal stent and 38.5% drug-eluting stent, drug-eluting stent showed the highest average cost per patient US$15,452.9±12,996.8 compared with bare-metal stent US$14,254.4±10,826.5. However, the effectiveness drug-eluting stent found were 97.44% (95% 92.48-100) regarding a bare-metal stent 81.67% (95% CI 71.88-91.46). The RCE was US$17,453.5 in the case of drug-eluting stent and US$15,829.6 with bare-metal stent, the RCEI was US$7,419. The acceptability curve shows that the treatment of drug-eluting stent becomes the dominant cost-effectiveness alternative from WTP US$15,109.9. The probabilistic analysis shows that drug-eluting stent is more cost effective when it exceeds US$21,153.8 WTP per patient. Conclusion: Drug-eluting stent is an alternative treatment interventional revascularization with better outcomes in health, and depending from the availability to pay can be a cost-effectiveness alternative to the institution.